纤维化间质性肺疾病患者细颗粒物暴露与肺功能及死亡率的关联
该多中心国际前瞻性队列纳入6683例纤维化间质性肺疾病患者,评估PM2.5及其成分暴露与基线肺功能、肺功能下降和死亡率的关联。PM2.5暴露≥8 μg/m3与死亡率升高的风险比在Simmons队列为4.40(95% CI, 3.51-5.51),在Pulmonary Fibrosis Foundation队列为1.71(95% CI, 1.32-2.21),在Canadian Registry for Pulmonary Fibrosis队列为1.45(95% CI, 1.18-1.79)。硫酸盐、硝酸盐和铵盐成分暴露增加与全队列死亡率升高相关,多成分模型显示这些成分与最不良结局相关。Meta分析显示硫酸盐和铵盐暴露与死亡率及FVC和DLCO下降速率一致相关,PM2.5多成分混合物水平升高与所有结局相关。作者认为需要减少人为污染源。
要点
- PM2.5暴露≥8 μg/m3与死亡率升高的HR在Simmons队列为4.40(95% CI, 3.51-5.51),Pulmonary Fibrosis Foundation队列为1.71(95% CI, 1.32-2.21),Canadian Registry for Pulmonary Fibrosis队列为1.45(95% CI, 1.18-1.79)。
- 硫酸盐、硝酸盐和铵盐PM2.5成分暴露增加与全队列死亡率升高相关,多成分模型显示这些成分与死亡率及基线肺功能的最不良结局相关。
- Meta分析显示硫酸盐和铵盐暴露与死亡率及FVC和DLCO下降速率一致相关,PM2.5多成分混合物水平升高与所有结局相关。
- 中位随访2.9年(IQR, 1.5-4.5年)期间,28%患者死亡,10%患者接受肺移植。
- 作者认为需要减少人为污染源。
适用人群与场景
- 纳入纤维化间质性肺疾病患者,来自Simmons间质性肺疾病注册中心(1424例)、Pulmonary Fibrosis Foundation注册中心42个站点(1870例)和Canadian Registry for Pulmonary Fibrosis注册中心8个站点(3389例),共6683例。
- 入组时中位年龄66岁(IQR, 58-73岁),男性3653例(55%),黑人205例(3.1%),白人5609例(84.0%)。
研究设计与关键结果
- 研究类型为多中心、国际、前瞻性队列研究,纳入6683例纤维化间质性肺疾病患者,数据分析时间为2021年6月1日至2022年8月2日。
- 暴露评估采用混合模型,结合卫星衍生气溶胶光学厚度、化学传输模型和地面PM2.5测量,估计PM2.5及其成分暴露。
- 主要结局分析:多变量线性回归检验入组前5年暴露与基线用力肺活量和一氧化碳弥散量的关联;多变量Cox模型检验删失前5年暴露与死亡率的关联;线性混合模型检验暴露与肺功能下降的关联;多成分分析采用基于分位数的g计算;队列效应估计进行Meta分析。
- 模型调整年龄、性别、吸烟史、种族、社会经济变量和站点(仅Pulmonary Fibrosis Foundation和Canadian Registry for Pulmonary Fibrosis队列)。
- 中位随访2.9年(IQR, 1.5-4.5年),28%患者死亡,10%患者接受肺移植。
- PM2.5暴露≥8 μg/m3与死亡率升高的HR:Simmons队列4.40(95% CI, 3.51-5.51),Pulmonary Fibrosis Foundation队列1.71(95% CI, 1.32-2.21),Canadian Registry for Pulmonary Fibrosis队列1.45(95% CI, 1.18-1.79)。
- 硫酸盐、硝酸盐和铵盐PM2.5成分暴露增加与全队列死亡率升高相关,多成分模型显示这些成分与死亡率及基线肺功能的最不良结局相关。
- Meta分析显示硫酸盐和铵盐暴露与死亡率及FVC和DLCO下降速率一致相关,PM2.5多成分混合物水平升高与所有结局相关。
证据类型、等级与局限
- 证据类型:多中心、国际、前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需要减少人为污染源。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Particulate matter 2.5 μm or less in diameter (PM2.5) is associated with adverse outcomes for patients with idiopathic pulmonary fibrosis, but its association with other fibrotic interstitial lung diseases (fILDs) and the association of PM2.5 composition with adverse outcomes remain unclear.
OBJECTIVE: To investigate the association of PM2.5 exposure with mortality and lung function among patients with fILD.
DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, international, prospective cohort study, patients were enrolled in the Simmons Center for Interstitial Lung Disease Registry at the University of Pittsburgh in Pittsburgh, Pennsylvania; 42 sites of the Pulmonary Fibrosis Foundation Registry; and 8 sites of the Canadian Registry for Pulmonary Fibrosis. A total of 6683 patients with fILD were included (Simmons, 1424; Pulmonary Fibrosis Foundation, 1870; and Canadian Registry for Pulmonary Fibrosis, 3389). Data were analyzed from June 1, 2021, to August 2, 2022.
EXPOSURES: Exposure to PM2.5 and its constituents was estimated with hybrid models, combining satellite-derived aerosol optical depth with chemical transport models and ground-based PM2.5 measurements.
MAIN OUTCOMES AND MEASURES: Multivariable linear regression was used to test associations of exposures 5 years before enrollment with baseline forced vital capacity and diffusion capacity for carbon monoxide. Multivariable Cox models were used to test associations of exposure in the 5 years before censoring with mortality, and linear mixed models were used to test associations of exposure with a decrease in lung function. Multiconstituent analyses were performed with quantile-based g-computation. Cohort effect estimates were meta-analyzed. Models were adjusted for age, sex, smoking history, race, a socioeconomic variable, and site (only for Pulmonary Fibrosis Foundation and Canadian Registry for Pulmonary Fibrosis cohorts).
RESULTS: Median follow-up across the 3 cohorts was 2.9 years (IQR, 1.5-4.5 years), with death for 28% of patients and lung transplant for 10% of patients. Of the 6683 patients in the cohort, 3653 were men (55%), 205 were Black (3.1%), and 5609 were White (84.0%). Median (IQR) age at enrollment across all cohorts was 66 (58-73) years. A PM2.5 exposure of 8 μg/m3 or more was associated with a hazard ratio for mortality of 4.40 (95% CI, 3.51-5.51) in the Simmons cohort, 1.71 (95% CI, 1.32-2.21) in the Pulmonary Fibrosis Foundation cohort, and 1.45 (95% CI, 1.18-1.79) in the Canadian Registry for Pulmonary Fibrosis cohort. Increasing exposure to sulfate, nitrate, and ammonium PM2.5 constituents was associated with increased mortality across all cohorts, and multiconstituent models demonstrated that these constituents tended to be associated with the most adverse outcomes with regard to mortality and baseline lung function. Meta-analyses revealed consistent associations of exposure to sulfate and ammonium with mortality and with the rate of decrease in forced vital capacity and diffusion capacity of carbon monoxide and an association of increasing levels of PM2.5 multiconstituent mixture with all outcomes.
CONCLUSIONS AND RELEVANCE: This cohort study found that exposure to PM2.5 was associated with baseline severity, disease progression, and mortality among patients with fILD and that sulfate, ammonium, and nitrate constituents were associated with the most harm, highlighting the need for reductions in human-derived sources of pollution.
参考来源
- Goobie GC, Carlsten C, Johannson KA, et al. Association of Particulate Matter Exposure With Lung Function and Mortality Among Patients With Fibrotic Interstitial Lung Disease. JAMA Intern Med. 2022. PMID: 36251286. doi:10.1001/jamainternmed.2022.4696
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。